2026 Q1 -tulosraportti
Vain PDF
95 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sittenI have started doing deeper analysis coverage on the STENOCARE case, which I share via my new Substack (frees up space for the thread here, which from time to time becomes somewhat messy and unserious). Latest post – "STENOCARE: From growth case to maturity plateau – what Q1/Q2 data and the 14-day rates reveal before the Q2 report" – is located here: 👉 https://xcapitalinvestor.substack.com/p/stenocare-fra-vkstcase-til-modenhedsplateau The format is new to me, so feedback is very welcome – both on content and whether it creates value for you. Happy Monday ☕
·3 t sittenIt is both stock status and clarification of the German legislation from July 10, 2026 ( I can't today after 12 PM as I usually do) Stock status Tübingen Apotheke is sold out for the first time. Their stock was emptied last Saturday. The pharmacy is one of the large ones in Germany. It is located in Baden-Württemberg, and when they report sold out, then Weeco Pharma must also not have any more Weeco Astrum 10/10 in their stock. Now the situation is that online stores are slowly starting to report completely sold out of Weeco Astrum 10/10. Cannano reports sold out The others we are monitoring only have a few pharmacies left that have the oil in stock. The pharmacies I can see that still have Weeco Astrum 10/10 in stock are. There is one pharmacy in each of these cities: Hamburg, Nürnberg, Düsseldorf and Nordrhein-Westfalen. Clarification of legislation as of July 10, 2026 The first link is from August 3. Where KVH (regional association of general practitioners) has sent out a message to all doctors, where they clarify the law change from. July 30, that flower medicine will have its subsidy permanently removed. As well as approved and standardized oils will not be affected by the quarantine. Weeco Astrum 10/10 is a standardized cannabis medicinal oil. But there has nevertheless been doubt about how the law change should be understood. Therefore, the doctors and health insurance funds have subsequently sat down together and issued a new message. Here it is established. That the announcement from the doctors on August 3 was correct. For information. It is very important for doctors and pharmacies that they also have the health insurance funds' word on how the new legislation should be understood. Because in Germany, there is the feared and hated regress system. It simply means that if doctors prescribe prescriptions that are not approved with 100% reimbursement, like Weeco Astrum10/10, and the doctors exceed the budget they are given every 3 months, the doctors will have to pay back out of their own pocket. As for the pharmacies, if they come to dispense medicine, here we are talking about flower medicine, after July 10, 2026, without the customer paying for the medicine, i.e., the pharmacies have dispensed flower medicine without taking payment for it, and sent the bill to the insurance company, as they have done for the last two years. These pharmacies that have not understood that since July 10, 2026, the customer should pay themselves, even if the prescription states that there is 100% reimbursement. Pharmacies must therefore pay themselves, out of their own pocket, because they do not receive reimbursement from the health insurance funds. This applies from July 10, 2026 It has emerged that some pharmacies incur an extra expense. Due to the above. ( I have written about the Regress system before, but a lot has happened since then, so I am writing about it again. I believe it is important knowledge to understand the reason why Weeco Pharma has so quickly run into bottleneck problems) The first one sent out by the medical associations. August 3 https://www.kvhh.net/de/praxis/verordnung/verordnung/wichtige-aenderungen-im-arzneimittelbereich-das-gkv-beitragssatzstabilisierungsgesetz-tritt-am-30-juli-2026-in-kraft.html Joint announcement from medical associations and health insurance funds. Doctors and health insurance funds. https://www.hanf-magazin.com/en/kbv-gkv-spitzenverband-klarstellung-cannabis-verordnung/- ·3 päivää sitten · MuokattuStock status Pink Bloom is sold out. Pink Bloom is a very large pharmacy located in Stuttgart. It's the first time they are sold out Canngo is from 2 to 4 pharmacies in stock The reason these two pharmacies got oil so quickly is probably because they bought the oil from other large pharmacies. When not everyone simply bought from the large pharmacies, it's because one needs permission for it. Flowzz has gone from 3 to 2 pharmacies. All pharmacies that have been sold out since Thursday, except those that can buy internally, are still sold out Now it's since July 29th that we saw the first pharmacies report sold out, and since pharmacies have started selling to each other, it's not because people have stopped buying Weeco Astrum 10/10, but because there are problems with delivery, PJ and TS cannot possibly be unaware of this.Today's figures for number of trades today Today, there have been traded, in number 216.979. Which is 2377% more than a normal trading day. 0,932 kr which is 1,69% down at closing time.
·3 päivää sittenI received this email today which I want to share https://news.cision.com/stenocare/r/france-reaches-important-milestone-towards-permanent-legalisation-of-medical-cannabis,c4380842- ·3 päivää sittenSTENOCARE: France reaches important milestone towards permanent legalization of medical cannabis today at 08:01 ∙ News overview (AI) STENOCARE positions its innovative medical cannabis oil, ASTRUM 10-10, for the upcoming permanent French framework for medical cannabis. A crucial regulatory decree, regulating product evaluation, pricing, and reimbursement, has been submitted to France's highest administrative court. This milestone marks an important step in France's transition from a pilot program to a fully regulated, sustainable market. The French reimbursement decree was submitted to the Conseil d'État on July 2, 2026, representing one of the last legal steps before formal adoption. STENOCARE targets the upcoming permanent framework with its ASTRUM 10-10 oil product by leveraging its advanced regulatory dossier and partnership in France. The future permanent framework will require a dual approval: product approval from ANSM and evaluation of the therapeutic benefit for reimbursement from HAS. France's transition to a permanent framework follows a national pilot program for medical cannabis, which has been running since 2021.
Just try to explain to me how a piece of news about France working towards a permanent scheme for medical cannabis relates to you believing that sales in Germany have exploded and that management is deliberately concealing this.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
95 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenI have started doing deeper analysis coverage on the STENOCARE case, which I share via my new Substack (frees up space for the thread here, which from time to time becomes somewhat messy and unserious). Latest post – "STENOCARE: From growth case to maturity plateau – what Q1/Q2 data and the 14-day rates reveal before the Q2 report" – is located here: 👉 https://xcapitalinvestor.substack.com/p/stenocare-fra-vkstcase-til-modenhedsplateau The format is new to me, so feedback is very welcome – both on content and whether it creates value for you. Happy Monday ☕
- ·3 t sittenIt is both stock status and clarification of the German legislation from July 10, 2026 ( I can't today after 12 PM as I usually do) Stock status Tübingen Apotheke is sold out for the first time. Their stock was emptied last Saturday. The pharmacy is one of the large ones in Germany. It is located in Baden-Württemberg, and when they report sold out, then Weeco Pharma must also not have any more Weeco Astrum 10/10 in their stock. Now the situation is that online stores are slowly starting to report completely sold out of Weeco Astrum 10/10. Cannano reports sold out The others we are monitoring only have a few pharmacies left that have the oil in stock. The pharmacies I can see that still have Weeco Astrum 10/10 in stock are. There is one pharmacy in each of these cities: Hamburg, Nürnberg, Düsseldorf and Nordrhein-Westfalen. Clarification of legislation as of July 10, 2026 The first link is from August 3. Where KVH (regional association of general practitioners) has sent out a message to all doctors, where they clarify the law change from. July 30, that flower medicine will have its subsidy permanently removed. As well as approved and standardized oils will not be affected by the quarantine. Weeco Astrum 10/10 is a standardized cannabis medicinal oil. But there has nevertheless been doubt about how the law change should be understood. Therefore, the doctors and health insurance funds have subsequently sat down together and issued a new message. Here it is established. That the announcement from the doctors on August 3 was correct. For information. It is very important for doctors and pharmacies that they also have the health insurance funds' word on how the new legislation should be understood. Because in Germany, there is the feared and hated regress system. It simply means that if doctors prescribe prescriptions that are not approved with 100% reimbursement, like Weeco Astrum10/10, and the doctors exceed the budget they are given every 3 months, the doctors will have to pay back out of their own pocket. As for the pharmacies, if they come to dispense medicine, here we are talking about flower medicine, after July 10, 2026, without the customer paying for the medicine, i.e., the pharmacies have dispensed flower medicine without taking payment for it, and sent the bill to the insurance company, as they have done for the last two years. These pharmacies that have not understood that since July 10, 2026, the customer should pay themselves, even if the prescription states that there is 100% reimbursement. Pharmacies must therefore pay themselves, out of their own pocket, because they do not receive reimbursement from the health insurance funds. This applies from July 10, 2026 It has emerged that some pharmacies incur an extra expense. Due to the above. ( I have written about the Regress system before, but a lot has happened since then, so I am writing about it again. I believe it is important knowledge to understand the reason why Weeco Pharma has so quickly run into bottleneck problems) The first one sent out by the medical associations. August 3 https://www.kvhh.net/de/praxis/verordnung/verordnung/wichtige-aenderungen-im-arzneimittelbereich-das-gkv-beitragssatzstabilisierungsgesetz-tritt-am-30-juli-2026-in-kraft.html Joint announcement from medical associations and health insurance funds. Doctors and health insurance funds. https://www.hanf-magazin.com/en/kbv-gkv-spitzenverband-klarstellung-cannabis-verordnung/
- ·3 päivää sitten · MuokattuStock status Pink Bloom is sold out. Pink Bloom is a very large pharmacy located in Stuttgart. It's the first time they are sold out Canngo is from 2 to 4 pharmacies in stock The reason these two pharmacies got oil so quickly is probably because they bought the oil from other large pharmacies. When not everyone simply bought from the large pharmacies, it's because one needs permission for it. Flowzz has gone from 3 to 2 pharmacies. All pharmacies that have been sold out since Thursday, except those that can buy internally, are still sold out Now it's since July 29th that we saw the first pharmacies report sold out, and since pharmacies have started selling to each other, it's not because people have stopped buying Weeco Astrum 10/10, but because there are problems with delivery, PJ and TS cannot possibly be unaware of this.Today's figures for number of trades today Today, there have been traded, in number 216.979. Which is 2377% more than a normal trading day. 0,932 kr which is 1,69% down at closing time.
- ·3 päivää sittenI received this email today which I want to share https://news.cision.com/stenocare/r/france-reaches-important-milestone-towards-permanent-legalisation-of-medical-cannabis,c4380842
- ·3 päivää sittenSTENOCARE: France reaches important milestone towards permanent legalization of medical cannabis today at 08:01 ∙ News overview (AI) STENOCARE positions its innovative medical cannabis oil, ASTRUM 10-10, for the upcoming permanent French framework for medical cannabis. A crucial regulatory decree, regulating product evaluation, pricing, and reimbursement, has been submitted to France's highest administrative court. This milestone marks an important step in France's transition from a pilot program to a fully regulated, sustainable market. The French reimbursement decree was submitted to the Conseil d'État on July 2, 2026, representing one of the last legal steps before formal adoption. STENOCARE targets the upcoming permanent framework with its ASTRUM 10-10 oil product by leveraging its advanced regulatory dossier and partnership in France. The future permanent framework will require a dual approval: product approval from ANSM and evaluation of the therapeutic benefit for reimbursement from HAS. France's transition to a permanent framework follows a national pilot program for medical cannabis, which has been running since 2021.Just try to explain to me how a piece of news about France working towards a permanent scheme for medical cannabis relates to you believing that sales in Germany have exploded and that management is deliberately concealing this.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
95 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sittenI have started doing deeper analysis coverage on the STENOCARE case, which I share via my new Substack (frees up space for the thread here, which from time to time becomes somewhat messy and unserious). Latest post – "STENOCARE: From growth case to maturity plateau – what Q1/Q2 data and the 14-day rates reveal before the Q2 report" – is located here: 👉 https://xcapitalinvestor.substack.com/p/stenocare-fra-vkstcase-til-modenhedsplateau The format is new to me, so feedback is very welcome – both on content and whether it creates value for you. Happy Monday ☕
- ·3 t sittenIt is both stock status and clarification of the German legislation from July 10, 2026 ( I can't today after 12 PM as I usually do) Stock status Tübingen Apotheke is sold out for the first time. Their stock was emptied last Saturday. The pharmacy is one of the large ones in Germany. It is located in Baden-Württemberg, and when they report sold out, then Weeco Pharma must also not have any more Weeco Astrum 10/10 in their stock. Now the situation is that online stores are slowly starting to report completely sold out of Weeco Astrum 10/10. Cannano reports sold out The others we are monitoring only have a few pharmacies left that have the oil in stock. The pharmacies I can see that still have Weeco Astrum 10/10 in stock are. There is one pharmacy in each of these cities: Hamburg, Nürnberg, Düsseldorf and Nordrhein-Westfalen. Clarification of legislation as of July 10, 2026 The first link is from August 3. Where KVH (regional association of general practitioners) has sent out a message to all doctors, where they clarify the law change from. July 30, that flower medicine will have its subsidy permanently removed. As well as approved and standardized oils will not be affected by the quarantine. Weeco Astrum 10/10 is a standardized cannabis medicinal oil. But there has nevertheless been doubt about how the law change should be understood. Therefore, the doctors and health insurance funds have subsequently sat down together and issued a new message. Here it is established. That the announcement from the doctors on August 3 was correct. For information. It is very important for doctors and pharmacies that they also have the health insurance funds' word on how the new legislation should be understood. Because in Germany, there is the feared and hated regress system. It simply means that if doctors prescribe prescriptions that are not approved with 100% reimbursement, like Weeco Astrum10/10, and the doctors exceed the budget they are given every 3 months, the doctors will have to pay back out of their own pocket. As for the pharmacies, if they come to dispense medicine, here we are talking about flower medicine, after July 10, 2026, without the customer paying for the medicine, i.e., the pharmacies have dispensed flower medicine without taking payment for it, and sent the bill to the insurance company, as they have done for the last two years. These pharmacies that have not understood that since July 10, 2026, the customer should pay themselves, even if the prescription states that there is 100% reimbursement. Pharmacies must therefore pay themselves, out of their own pocket, because they do not receive reimbursement from the health insurance funds. This applies from July 10, 2026 It has emerged that some pharmacies incur an extra expense. Due to the above. ( I have written about the Regress system before, but a lot has happened since then, so I am writing about it again. I believe it is important knowledge to understand the reason why Weeco Pharma has so quickly run into bottleneck problems) The first one sent out by the medical associations. August 3 https://www.kvhh.net/de/praxis/verordnung/verordnung/wichtige-aenderungen-im-arzneimittelbereich-das-gkv-beitragssatzstabilisierungsgesetz-tritt-am-30-juli-2026-in-kraft.html Joint announcement from medical associations and health insurance funds. Doctors and health insurance funds. https://www.hanf-magazin.com/en/kbv-gkv-spitzenverband-klarstellung-cannabis-verordnung/
- ·3 päivää sitten · MuokattuStock status Pink Bloom is sold out. Pink Bloom is a very large pharmacy located in Stuttgart. It's the first time they are sold out Canngo is from 2 to 4 pharmacies in stock The reason these two pharmacies got oil so quickly is probably because they bought the oil from other large pharmacies. When not everyone simply bought from the large pharmacies, it's because one needs permission for it. Flowzz has gone from 3 to 2 pharmacies. All pharmacies that have been sold out since Thursday, except those that can buy internally, are still sold out Now it's since July 29th that we saw the first pharmacies report sold out, and since pharmacies have started selling to each other, it's not because people have stopped buying Weeco Astrum 10/10, but because there are problems with delivery, PJ and TS cannot possibly be unaware of this.Today's figures for number of trades today Today, there have been traded, in number 216.979. Which is 2377% more than a normal trading day. 0,932 kr which is 1,69% down at closing time.
- ·3 päivää sittenI received this email today which I want to share https://news.cision.com/stenocare/r/france-reaches-important-milestone-towards-permanent-legalisation-of-medical-cannabis,c4380842
- ·3 päivää sittenSTENOCARE: France reaches important milestone towards permanent legalization of medical cannabis today at 08:01 ∙ News overview (AI) STENOCARE positions its innovative medical cannabis oil, ASTRUM 10-10, for the upcoming permanent French framework for medical cannabis. A crucial regulatory decree, regulating product evaluation, pricing, and reimbursement, has been submitted to France's highest administrative court. This milestone marks an important step in France's transition from a pilot program to a fully regulated, sustainable market. The French reimbursement decree was submitted to the Conseil d'État on July 2, 2026, representing one of the last legal steps before formal adoption. STENOCARE targets the upcoming permanent framework with its ASTRUM 10-10 oil product by leveraging its advanced regulatory dossier and partnership in France. The future permanent framework will require a dual approval: product approval from ANSM and evaluation of the therapeutic benefit for reimbursement from HAS. France's transition to a permanent framework follows a national pilot program for medical cannabis, which has been running since 2021.Just try to explain to me how a piece of news about France working towards a permanent scheme for medical cannabis relates to you believing that sales in Germany have exploded and that management is deliberately concealing this.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt